ATM and non-small cell lung carcinoma: These data have important clinical implications as they suggest that AZD6738 has the potential to enhance the efficacy-of-standard of care treatments in > 150,000 NSCLC patients in the USA each year, particularly those harboring ATM-deficient tumors.